German Company CureVac announced on Wednesday the final results of its late-stage vaccine trial, confirming earlier data showing that its shot is far less protective than other vaccines. The vaccine had an efficacy of just 48% against Covid-19.
The Moderna and Pfizer-BioNTech vaccines, which use the same mRNA technology as CureVac’s, delivered efficacy rates of around 95% in clinical trials.CureVac’s vaccine proved somewhat better for younger volunteers like those between the ages of 18 and 60, the efficacy rose to 53%. In that group, the researchers also found the vaccine provided 100% protection against hospitalization and death.
The vaccine experts have also questioned whether part of CureVac’s problem was with the design of the vaccine itself. The precise recipe that German Company CureVac used to build its vaccine may have blunted its effectiveness. Weissman’s research has shown that using messenger RNA without modifications can interfere with T cells involved in developing a robust immune response.The European Medicines Agency opened a rolling review of CureVac’s vaccine in February, and the company said it would continue its submission with this data. The vaccine will be an important contribution to help manage the Covid-19 pandemic and the dynamic variant spread.